News

According to the company, in both the trials ‘bivalent rLP2086’ was observed to generate bactericidal responses, a measurement of functional immune response, against diverse meningococcal serogroup B test

Ohr Pharmaceutical CEO Dr Irach B. Taraporewala noted that the company is excited to be working with such a prestigious group of retina specialists in this important early

The two parties will jointly develop and produce Fondaparinux, an anti-thrombotic agent and Travoprost and Bimatoprost, two prostaglandin derivative drugs for treating glaucoma. Capitalizing on the strengths and

Dr Janet Sweeney PhD and Corrie Yelland founders of the Phoenix Tears Foundation have been helping cancer patients with Cannabis based medicines while documenting their research since 2006.

The amended agreements provide ProMetic back with the effective control of NantPro and a greater portion of the future value and revenues associated with the development and sales

CHPA’s comments underscored its support for the FDA’s re-examination of the system in an effort to complete the OTC Drug Review. CHPA believes this can best be accomplished

Psoriasis is a non-contagious chronic disease in which the immune system causes skin cells to grow at a faster rate. The company said that the trial met all

The drug is a combination of umeclidinium(UMEC), a long-acting muscarinic antagonist (LAMA) that helps lung function, and vilanterol (VI), a long-acting beta2 agonist (LABA), in a single inhaler,

The investigational regimen includes the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (ABT-267) 25mg, dosed once daily, and dasabuvir (ABT-333) 250mg with or without ribavirin (weight-based), dosed